2 weeks Ago By Defense World Staff
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX – Get Free Report )’s stock price reached a new 52-week high during trading on Thursday after Citigroup raised their price target on the stock from $70.00 to $74.
00. Citigroup currently has a buy rating on the stock. Crinetics Pharmaceuticals traded as high as $62.
53 and last traded at $62.00, with a volume of 320685 shares changing hands. The stock had previously closed at $58.
92. Several other analysts have also commented on the company. HC Wainwright raised their target price on Crinetics Pharmaceuticals from $69.
00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.
00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, September 16th. Oppenheimer reiterated an “outperform” rating and issued a $73.00 target price (down from $74.
00) on shares of Crinetics Pharmaceuticals in a research note on Friday, August 9th. Finally, JMP Securities restated a “market outperform” rating and set a $80.00 target price on shares of Crinetics Pharmaceuticals in a research report on Friday, September 27th.
One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.
18. Read Our Latest Analysis on CRNX Insider Buying and Selling Institutional Trading of Crinetics Pharmaceuticals Several large investors have recently added to or reduced their stakes in the stock. Comerica Bank acquired a new position in shares of Crinetics Pharmaceuticals during the 1st quarter valued at about $33,000.
Quest Partners LLC acquired a new position in Crinetics Pharmaceuticals in the 2nd quarter valued at about $42,000. Values First Advisors Inc. purchased a new stake in shares of Crinetics Pharmaceuticals in the 3rd quarter valued at approximately $84,000.
Allspring Global Investments Holdings LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the 3rd quarter worth approximately $91,000. Finally, KBC Group NV increased its holdings in shares of Crinetics Pharmaceuticals by 22.8% during the 3rd quarter.
KBC Group NV now owns 2,193 shares of the company’s stock worth $112,000 after buying an additional 407 shares during the last quarter. 98.51% of the stock is currently owned by hedge funds and other institutional investors.
Crinetics Pharmaceuticals Stock Performance The stock has a market cap of $4.77 billion, a PE ratio of -15.99 and a beta of 0.
62. The company’s 50-day moving average price is $54.88 and its 200 day moving average price is $51.
15. Crinetics Pharmaceuticals ( NASDAQ:CRNX – Get Free Report ) last posted its earnings results on Tuesday, November 12th. The company reported ($0.
96) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.05).
During the same quarter in the prior year, the firm posted ($1.01) earnings per share. As a group, equities research analysts predict that Crinetics Pharmaceuticals, Inc.
will post -3.72 earnings per share for the current fiscal year. About Crinetics Pharmaceuticals ( Get Free Report ) Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. See Also Five stocks we like better than Crinetics Pharmaceuticals How to Invest in Biotech Stocks 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story Mouse Rising: The Iger Investment Pays Off for Disney Investors Investing In Preferred Stock vs. Common Stock Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
